{
  "docId": "019de073-e8d5-735f-8ffd-8a5102406a96",
  "docSlug": "3003a94fa3be7c8f2ff0fbac5a54b26e",
  "documentTitle": "Arbutus Biopharma | Results Presentation Deck | 15 slides",
  "authorId": "arbutus-biopharma",
  "authorName": "Arbutus Biopharma",
  "documentKindSlug": "conference-presentation",
  "documentKindLabel": "Conference presentation",
  "sourceTypeSlug": "investor_relations",
  "sourceTypeLabel": "Investor relations",
  "presentationDate": "2022-11-01 00:00:00",
  "orientation": "landscape",
  "aspectRatio": 1.7777778,
  "pageNumber": 12,
  "pageCount": 15,
  "prevPage": 11,
  "nextPage": 13,
  "slideType": "before_after",
  "function": "analyze_data",
  "density": "balanced",
  "nDataPoints": 6,
  "notes": "The slide uses a timeline-based experimental design on the left and a dot plot showing PD-L1 expression levels on the right.",
  "elementsJson": null,
  "metadataConfidence": 1,
  "imagePath": null,
  "slideHref": "/slides/019de073-e8d5-735f-8ffd-8a5102406a96/12",
  "deckHref": "/decks/019de073-e8d5-735f-8ffd-8a5102406a96",
  "deckJsonHref": "/decks/019de073-e8d5-735f-8ffd-8a5102406a96.json",
  "deckAnchorHref": "/decks/019de073-e8d5-735f-8ffd-8a5102406a96#slide-12",
  "components": [
    {
      "bbox": {
        "h": 0.55,
        "w": 0.3,
        "x": 0.65,
        "y": 0.25
      },
      "kind": "chart",
      "text": "Dot plot showing % PD-L1+ Kupffer cells across different treatment groups.",
      "attrs": null,
      "subkind": "dot",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "97ecb6ee-5111-4b3a-85a9-1b9bf251612c",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.65,
        "w": 0.55,
        "x": 0.07,
        "y": 0.21
      },
      "kind": "diagram",
      "text": "Experimental design timeline showing dosing schedules for GalNAc-siRNA, AB-101, and Atezolizumab.",
      "attrs": null,
      "subkind": "timeline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "5047eea5-8fcb-43fd-ba22-f732ffeb25f5",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.12,
        "w": 0.85,
        "x": 0.07,
        "y": 0.05
      },
      "kind": "title",
      "text": "AB-101: Demonstrates Target Engagement in CD8+ Kupffer Cells in a cHBV Mouse Model",
      "attrs": null,
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "2594a55b-9a0a-459e-b2de-8681b03c914f",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.04,
        "w": 0.3,
        "x": 0.65,
        "y": 0.21
      },
      "kind": "title",
      "text": "AB-101 Treatment Reduces PD-L1 in Liver",
      "attrs": null,
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "2b5093ce-dafc-4439-9c7f-67b281564209",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [
    {
      "name": "Before-After-Bridge",
      "slug": "before-after-bridge",
      "agent": "Storyteller",
      "layer": "slide",
      "matchId": "2e25a7d8-2bf0-4c1c-ada5-56b305019dab",
      "evidence": "AB-101 treatment significantly reduces PD-L1 expression in Kupffer cells in a cHBV mouse model.",
      "confidence": 0.7
    }
  ],
  "frameworks": [],
  "arcBeats": [],
  "loops": [],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}